Avidity Biosciences, Inc. (RNA)
| Market Cap | 11.29B +175.9% |
| Revenue (ttm) | 18.76M +106.3% |
| Net Income | -684.63M |
| EPS | -4.97 |
| Shares Out | 155.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 72.80 |
| Day's Range | n/a |
| 52-Week Range | 21.51 - 73.06 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 69.26 (-4.86%) |
| Earnings Date | Feb 27, 2026 |
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular d... [Read more]
Analyst Summary
According to 20 analysts, the average rating for RNA stock is "Buy." The 12-month stock price target is $69.26, which is a decrease of -4.86% from the latest price.
News
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinic...
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligon...
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligon...
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated improvements in multiple measures i...
Avidity Biosciences Announces Expected Record Date for Spin-Off
SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonu...
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypoch...
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.
Top 2 Health Care Stocks That May Keep You Up At Night In December
As of Dec. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company...
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avidi...
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.
Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday
Shares of Avidity Biosciences (RNA) soared more than 40% Monday after Novartis (NVS) agreed to buy the U.S. biopharmaceutical firm for about $12 billion in cash to expand its RNA-based disease-fightin...
Is it too late to buy Avidity stock after Novartis deal?
Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announcem...
Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk
President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week. Novartis announced it will buy Avidity Biosciences.
Wall Street Breakfast Podcast: Novartis Puts $12B On The Table
Avidity Biosciences (RNA) surges 42% premarket after Novartis agrees to acquire the company for $12 billion, paying $72 per share in cash. The RNA deal signals renewed Big Pharma interest in RNA thera...
Novartis shares slip, Avidity soars after $12 billion biotech deal
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CE...
Novartis Agrees $12 Billion Biotech Deal for Avidity
Novartis agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker's biggest acquisition in more than a decade and adding several potential blockbuster...
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Novartis to acquire Avidity Biosciences for about $12B
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for...
Novartis Deal Values Avidity Biosciences At $12 Billion
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Novartis to acquire Avidity Biosciences for $12 billion
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.